Search
Moderna Inc
MRNAAdd to Watchlist
52.920USD
-1.430-2.63%
Close 05/11, 16:00（ET）Quotes delayed by 15 min
21.01BMarket Cap
LossP/E TTM
More Details of Moderna Inc Company
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Moderna Inc Info
Ticker SymbolMRNA
Company nameModerna Inc
IPO dateDec 07, 2018
CEOBancel (Stephane)
Number of employees5800
Security typeOrdinary Share
Fiscal year-endDec 07
Address325 Binney Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone16177146500
Websitehttps://www.modernatx.com/
Ticker SymbolMRNA
IPO dateDec 07, 2018
CEOBancel (Stephane)
Company Executives of Moderna Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.63M
--
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
65.78K
+9.26%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
57.75K
+1.30%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
19.32K
+84.03%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
4.76K
+85.23%
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Francois Nader, M.D.
Dr. Francois Nader, M.D.
Independent Director
Independent Director
--
--
Ms. Tracey Franklin
Ms. Tracey Franklin
Chief People and Digital Technology Officer
Chief People and Digital Technology Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.63M
--
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
--
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
65.78K
+9.26%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
57.75K
+1.30%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
19.32K
+84.03%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
4.76K
+85.23%
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
COVID
1.81B
99.56%
RSV
8.00M
0.44%
By RegionUSD
Name
Revenue
Proportion
United States
1.20B
65.95%
Rest of the World
692.00M
38.06%
Europe
53.00M
2.92%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
COVID
1.81B
99.56%
RSV
8.00M
0.44%
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
6.74%
Vanguard Capital Management, LLC
5.76%
BlackRock Institutional Trust Company, N.A.
5.30%
Baillie Gifford & Co.
5.04%
State Street Investment Management (US)
4.12%
Other
73.03%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
6.74%
Vanguard Capital Management, LLC
5.76%
BlackRock Institutional Trust Company, N.A.
5.30%
Baillie Gifford & Co.
5.04%
State Street Investment Management (US)
4.12%
Other
73.03%
Shareholder Types
Shareholders
Proportion
Investment Advisor
45.49%
Investment Advisor/Hedge Fund
14.13%
Hedge Fund
10.11%
Corporation
4.56%
Research Firm
4.35%
Individual Investor
2.71%
Bank and Trust
1.75%
Venture Capital
1.17%
Pension Fund
1.02%
Other
14.71%
Institutional Shareholding
Updated: Sun, Apr 5
Updated: Sun, Apr 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
1886
313.06M
78.90%
+10.10M
2025Q4
1870
297.93M
76.26%
-17.82M
2025Q3
1925
289.85M
74.21%
-20.82M
2025Q2
2015
310.55M
79.82%
-10.63M
2025Q1
2127
325.75M
84.24%
-21.87M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
26.73M
6.74%
+14.44M
+117.58%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
21.04M
5.31%
+1.05M
+5.23%
Dec 31, 2025
Baillie Gifford & Co.
20.58M
5.19%
-1.27M
-5.80%
Dec 31, 2025
State Street Investment Management (US)
16.37M
4.13%
-743.12K
-4.34%
Dec 31, 2025
Two Sigma Investments, LP
15.07M
3.8%
+768.91K
+5.38%
Dec 31, 2025
Capital World Investors
12.83M
3.23%
+12.83M
--
Dec 31, 2025
Geode Capital Management, L.L.C.
9.22M
2.32%
-29.71K
-0.32%
Dec 31, 2025
Boston Biotech Ventures, L.L.C.
9.21M
2.32%
--
--
Mar 09, 2026
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
3.72%
Global X Genomics & Biotechnology ETF
3.52%
First Trust NYSE Arca Biotechnology Index Fund
3.4%
Langar Global HealthTech ETF
3.2%
WisdomTree BioRevolution Fund
2.72%
State Street SPDR S&P Biotech ETF
2.19%
VanEck Biotech ETF
1.82%
Invesco S&P 500 Equal Weight Health Care ETF
1.82%
iShares Health Innovation Active ETF
1.72%
ROBO Global Healthcare Technology & Innovation ETF
1.6%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion3.72%
Global X Genomics & Biotechnology ETF
Proportion3.52%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.4%
Langar Global HealthTech ETF
Proportion3.2%
WisdomTree BioRevolution Fund
Proportion2.72%
State Street SPDR S&P Biotech ETF
Proportion2.19%
VanEck Biotech ETF
Proportion1.82%
Invesco S&P 500 Equal Weight Health Care ETF
Proportion1.82%
iShares Health Innovation Active ETF
Proportion1.72%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.6%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
